Skip to main content

Table 5 Treatment uptake in study cohorts of people who inject drugs (current and former)

From: A systematic review of Hepatitis C virus treatment uptake among people who inject drugs in the European Region

Author, year % treated (# treated/# of treatment candidates SVR (%) (# with sustained viral response/# treated)
Broers et al, 2005 61% of RNA+ (11/18) Intent-to-treat: 56% (6/11)
As-treated: 100% (3/3)
Cournot et al, 2004 39% of antibody+ (58/150) Intent-to-treat: 22% (15/68)1
  57% of RNA+ (58/102)  
  71% of other (58/82)  
Crespo et al, 2001 64% of antibody+ (268/416) NA
Gazdag et al, 2010 47% of RNA+ (39/83) NA
Guadagnino et al, 2007 31% of RNA+ (53/169) Intent-to-treat: 55% (29/53)
As-treated: 85% (29/34)
Hernandez et al, 2009 0% of RNA+ (0/4) NA
Jowett et al, 2000 20% of antibody+ (50/253) Intent-to-treat: 36% (18/50)
  29% of RNA+ (50/172)  
  50% of other (50/100)  
Kieran et al, 2011 21% of RNA+ (67/327) Intent-to-treat: 43% (29/67)
Perez-Alvarez et al, 2012 56% of RNA+ (15/27) NA
Reiberger et al, 2011 32% of RNA+ (201/637) NA
van der Veen, 2009 48% of RNA+ (35/73) NA
  1. Antibody+ = study participants who are hepatitis C antibody-positive
  2. RNA+ = study participants who are hepatitis C RNA-positive
  3. Other = study participants who are hepatitis C RNA-positive and meet additional treatment criteria
  4. 1. Calculated according to the number of treatment outcomes (N=68) rather than the number of patients who initiated therapy (N=58)